Granules India Opens Two R&D Centres at IIT Hyderabad
Filing Summary
Granules India Limited inaugurated two Centres of Excellence at IIT Hyderabad’s Technology Research Park on December 1, 2025. The Ascelis Center focuses on peptide development and characterization, while the Granules Center advances particle engineering. These facilities aim to enhance Granules’ research capabilities in peptides and material sciences. The centres will collaborate with Granules’ Swiss-based R&D facility, Senn Chemicals, to integrate global peptide offerings. Granules India, a pharmaceutical company, operates in over 80 countries with 11 manufacturing facilities and holds multiple regulatory approvals.
On December 1, 2025, Granules India Limited inaugurated two new Centres of Excellence at the Technology Research Park of IIT Hyderabad. The facilities are the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.
The Ascelis Center, established under Ascelis Peptides, focuses on the development and characterization of cosmetic, therapeutic, and pharmaceutical peptides. It is the first such facility in India for Ascelis and is equipped for primary, secondary, and tertiary structure characterization. This center will collaborate with Granules’ Swiss-based R&D facility, Senn Chemicals, to enhance the company’s integrated global peptide offerings.
The Granules Center of Excellence for Particle Engineering will focus on polymorph research, material science, and novel drug delivery systems, including amorphous solid dispersions. This facility replaces previous external and ad-hoc development efforts with a dedicated research platform. It aims to enable first-to-file opportunities and support the creation of proprietary technologies for regulated markets.
Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, led the inauguration along with Mrs. Uma Chigurupati, Executive Director, and Prof. B S Murty, Director of IIT Hyderabad. The new centres are expected to enhance Granules’ capabilities in peptides and advanced material sciences.
Granules India Limited, incorporated in 1991, is a vertically integrated pharmaceutical company. It operates across the entire value chain, from Active Pharmaceutical Ingredients (APIs) to Finished Dosages (FDs) and Peptides CDMO. The company distributes products to over 300 customers in more than 80 countries and has 11 manufacturing facilities, with regulatory approvals from agencies including US FDA, EDQM, and EU GMP.